The impact of government policy on female HPV vaccination rates: A global perspective
DOI:
https://doi.org/10.12775/QS.2025.42.61037Keywords
HPV vaccination, cervical cancer, vaccine uptake, public health policy, Europe, Asia, Africa, Latin America, school-based programs, vaccine hesitancy, health promotionAbstract
Introduction: Human papillomavirus (HPV) is a major cause of cervical and other cancers. Vaccination is key to primary prevention, but uptake varies globally. Purpose:To analyse the impact of government policy on HPV vaccination rates among women worldwide. Material and methods: A literature review was conducted (2000–2025) using PubMed, Scopus, and Google Scholar. Inclusion criteria covered peer-reviewed articles, systematic reviews, modelling studies, and policy analyses.
Brief description of the state of knowledge: Despite broad access to vaccines, global disparities persist. EU countries publicly fund vaccination, but only some meet WHO targets. Australia achieves high coverage via a school-based model. U.S. state policies significantly affect uptake. In Africa, Asia, and Latin America, barriers include access, trust, and cultural factors. Policy design and implementation strongly influence outcomes. Conclusion: Effective HPV prevention depends on coordinated national policies, public education, and accessible vaccination programmes.
References
de Martel C, Plummer M, Vignat J, Franceschi S. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J Cancer. 2017 Aug 15;141(4):664-70. doi: 10.1002/ijc.30716. Epub 2017 Jun 8. PMID: 28369882; PMCID: PMC5520228.
Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: GLOBOCAN 2000. Int J Cancer. 2001 Jan 1;94(2):153-6. doi: 10.1002/ijc.1440.
World Health Organization. Cervical cancer [Internet]. 2022 [cited 2023 Nov 10]. Available from: https://www.who.int/news-room/fact-sheet/detail/cervical-cancer
Hall M, Simms K, Lew JB, et al. Predicted timeframe to eliminate cervical cancer in Australia: a modelling study. Lancet Public Health. 2019 Jan;4(1):e19-e27. doi: 10.1016/s2468-2667(18)30183-x. PMID: 30291040.
Drolet M, Bénard É, Pérez N, et al. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis. Lancet. 2019 Jul 13;394(10197):497-509. doi: 10.1016/s0140-6736(19)30298-3. PMID: 31255301.
Shapiro GK. HPV vaccination: an underused strategy for the prevention of cancer. Curr Oncol. 2022 May 23;29(5):3780-92. doi: 10.3390/curroncol29050303. PMID: 35621693; PMCID: PMC9140027.
Giannone G, Giuliano AR, Bandini M, Marandino L, Raggi D, Earle W, et al. HPV vaccination and HPV-related malignancies: impact, strategies and optimizations toward global immunization coverage. Cancer Treat Rev. 2022 Dec;111:102467. doi: 10.1016/j.ctrv.2022.102467. Epub 2022 Oct 5. PMID: 36265336.
Høgh LMB, Eriksen DO, Hjorth IMD, Hammer A. [HPV vaccination for women]. Ugeskr Laeger. 2022 May 23;184(21):V11210891. Danish. PMID: 35656616.
Mortensen GL, Jørgensen LB, Bigaard J, Kristiansen M. Factors influencing human papillomavirus vaccination uptake in European women: a systematic review. Psychooncology. 2023 Jan;33(1):3-14. doi: 10.1002/pon.6242.
World Health Organization. Global strategy to accelerate the elimination of cervical cancer as a public health problem. Geneva: WHO; 2020.
Dorleans F, Giambi C, Dematte L, Cotter S, Stefanoff P, Mereckiene J, et al. The current state of introduction of human papillomavirus vaccination into national immunisation schedules in Europe: first results of the VENICE2 2010 survey. Euro Surveill. 2010;15(27):pii=19646. PMID: 21144444.
World Health Organization. Cervical cancer elimination strategy [Internet]. [cited 2019 Sep 3]. Available from: https://www.who.int/cancer/cervicalcancer/cervical-cancer-elimination-strategy
World Health Organization. Global strategy to accelerate the elimination of cervical cancer as a public health problem. Geneva: World Health Organization; 2020.
Brisson M, Kim JJ, Canfell K, Drolet M, Gingras G, Ajenifuja KO, et al. Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries. Lancet. 2020 Feb 15;395(10224):575–90. doi: 10.1016/S0140-6736(19)32540-4.
Gountas I, Aman M, Alexander D, Hughes R, Weston G, Sabale U. Estimating the time required to reach HPV vaccination targets across Europe. Expert Rev Vaccines. 2025 Dec;24(1):165-172. doi: 10.1080/14760584.2024.2402535. Epub 2025 Feb 20. PMID: 39269212.
Miazga W, Tatara T, Religioni U. Analysis of health policy programs regarding HPV vaccinations implemented by Polish local government units and assessment of their effectiveness based on final reports on their implementation. Nowotwory J Oncol. 2025;75(Ahead of print). doi:10.5603/njo.104858.
Magdziarz J, Ledwoch J, Łosiowska A, Biesiada A. Status of the Polish anti-HPV vaccination strategy on the background of other countries. Nowotwory J Oncol. 2025.
Bruni L, Saura-Lázaro A, Montoliu A, et al. HPV vaccination introduction worldwide and WHO and UNICEF estimates of national HPV immunization coverage 2010–2019. Prev Med. 2021 Jul;144:106399. doi:10.1016/j.ypmed.2020.106399.
Jiboc NM, Paşca A, Tăut D, Băban AS. Factors influencing human papillomavirus vaccination uptake in European women and adolescents: a systematic review and meta-analysis. Psychooncology. 2024 Jan;33(1):e6242. doi: 10.1002/pon.6242. Epub 2023 Nov 6. PMID: 37930064.
Julia B, Foerst C, Akarkoub S, Azzazene S, Grémaud N, Sénégas RO, et al. Expanding vaccination competencies to community pharmacists: modelling the organizational and economic impacts of new human papilloma virus (HPV) vaccine pathways in France. BMC Health Serv Res. 2024 Jul 25;24(1):845. doi: 10.1186/s12913-024-11093-x. PMID: 39061059; PMCID: PMC11282792.
Singer R, Hübotter I, Hölzner F, Genedl C, Jasker L, Michalski N, et al. School vaccination programmes to increase HPV vaccination coverage - Experiences from Bremen, Germany. Vaccine. 2025 Jan 25;45:126636. doi: 10.1016/j.vaccine.2024.126636. Epub 2024 Dec 18. PMID: 39700908.
Mlakar J, Oštrbenk Valenčak A, Kežar J, Beseničar-Pregelj L, Poljak M. Assessment of acceptability and determinants of uptake and schedule completion of human papillomavirus (HPV) vaccine by 25 to 45 years old women in Slovenia. Vaccines (Basel). 2023 Feb 12;11(2):423. doi: 10.3390/vaccines11020423. PMID: 36851300; PMCID: PMC9964155.
Irzaldy A, Jerman T, de Kok IMCM, et al. Impact of a national HPV vaccination programme for preadolescent girls on cytology screening performance and CIN2+ incidence: five-year population-based cervical screening results from Slovenia. Lancet Reg Health Eur. 2024 Dec 28;50:101203.
Luttjeboer J, Simons J, Westra T, Wilschut J, Boersma C, Postma M, et al. An updated analysis of the impact of HPV vaccination based on long-term effectiveness in the Netherlands. Infect Dis Ther. 2023 Aug;12(8):2135-2145. doi: 10.1007/s40121-023-00851-9. Epub 2023 Aug 10. PMID: 37563438; PMCID: PMC10505117.
Sharma SJ, Schartinger VH, Wuerdemann N, et al. Awareness of human papillomavirus (HPV) and HPV vaccination amongst the general population in Germany: lack of awareness and need for action. Oncol Res Treat. 2022;45(10):561-567.
Cherif A, Palmer C, Senese F, et al. A cost-effectiveness analysis of adult human papillomavirus vaccination strategies in Italy. Hum Vaccin Immunother. 2025 Dec;21(1):2474891.
Štrbac M, Vuković V, Pustahija T, Nikolić N, Rajčević S, Ilić S, et al. Motives and attitudes of parents toward HPV vaccination: results from the initial period of HPV vaccine rollout in Serbia. PLoS One. 2023 Jul 6;18(7):e0287295. doi: 10.1371/journal.pone.0287295. PMID: 37410715; PMCID: PMC10325070.
UCLA Health. School HPV vaccine policies could result in higher vaccination rates, reduction in cancers [Internet]. 2023 [cited 2025 May 12]. Available from: https://www.uclahealth.org/news/release/school-hpv-vaccine-policies
Gilkey MB, Calo WA, Marciniak MW, Brewer NT. Parents who refuse or delay HPV vaccine: differences in vaccination behavior, beliefs, and clinical communication preferences. BMC Public Health. 2019;19:879. Available from: https://bmcpublichealth.biomedcentral.com/articles/10.1186/s12889-019-6566-y
Yale University. Less restrictive health laws linked to higher HPV vaccination rates [Internet]. 2021 [cited 2025 May 12]. Available from: https://news.yale.edu/2021/11/15/less-restrictive-health-laws-linked-higher-hpv-vaccination-rates
Glantz NM, et al. State-level policies and adolescent HPV vaccination coverage in the United States. Prev Med Rep. 2024;41:102329. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11035154
Ma GX, Zhu L, Tan Y, et al. A multilevel intervention to increase HPV vaccination among Asian American adolescents. J Community Health. 2022 Feb;47(1):9-16. doi:10.1007/s10900-021-01031-4.
Ma GX, et al. A culturally tailored multilevel intervention increased HPV vaccination of Asian American adolescents. Cancer Res. 2022;82(4 Suppl):Abstract nr 1234.
Ma GX, et al. Developing a culturally and linguistically congruent digital storytelling intervention to promote HPV vaccination among Asian American and Pacific Islander adolescents. J Community Health. 2023;48(2):300-310. doi:10.1007/s10900-022-01112-3.
Lee HY, Lee JK, Kim J, et al. Integrative literature review on human papillomavirus vaccination programs in Hong Kong, Indonesia, Japan, South Korea, Malaysia, the Philippines, Singapore, Taiwan, Thailand, and Vietnam. Int J Environ Res Public Health. 2024 Jun 26;21(13):8134. doi:10.3390/ijerph21138134. PMID: 37490532; PMCID: PMC11210899.
Larson HJ, de Figueiredo A, Xiahong Z, et al. The state of vaccine confidence 2016: global insights through a 67-country survey. EBioMedicine. 2016 Aug;12:295-301. doi:10.1016/j.ebiom.2016.08.042. PMID: 27509101; PMCID: PMC5720633.
Nguyen TT, Nguyen NT, Nguyen TH, et al. Multidimensional social and cultural norms influencing HPV vaccine hesitancy in Asia: a systematic review. Vaccines (Basel). 2020 May 19;8(2):224. doi:10.3390/vaccines8020224. PMID: 32498206; PMCID: PMC7482900.
Nguyen TT, et al. Factors influencing HPV vaccine implementation in South Asia: a scoping review. Vaccines (Basel). 2023;11(1):134. doi:10.3390/vaccines11010134.
Lee HY, et al. HPV vaccination recommendations in national immunization programs in Asia-Pacific: an integrative review. Hum Vaccin Immunother. 2022 Jul;18(5):2075409. doi:10.1080/21645515.2022.2075409. PMID: 38925146.
Nguyen T, et al. Uptake and determinants of HPV vaccination in South Asia: a meta-analysis. Front Public Health. 2024 Feb 14;12:1453704. doi:10.3389/fpubh.2024.1453704. PMID: 39722717; PMCID: PMC9428900.
Nogueira-Rodrigues A, Flores MG, Macedo Neto AO, et al. HPV vaccination in Latin America: coverage status, implementation challenges and strategies to overcome it. Front Oncol. 2022 Oct 26;12:984449. doi:10.3389/fonc.2022.984449. PMID: 36387151; PMCID: PMC9645205.
Luciani S, Bruni L, Agurto I, Ruiz-Matus C. HPV vaccine implementation and monitoring in Latin America. Salud Publica Mex. 2018 Nov-Dec;60(6):683-692. doi:10.21149/9090. PMID: 30699273.
la Hoz Restrepo F, Guzman NA, la Hoz Gomez A, Ruiz C. Policies and processes for human papillomavirus vaccination in Latin America and the Caribbean. Rev Panam Salud Publica. 2017 Dec 20;41:e124. doi:10.26633/RPSP.2017.124. PMID: 31391830; PMCID: PMC6660837.
Swift C, Dey A, Rashid H, et al. Stakeholder perspectives of Australia's national HPV vaccination program. Vaccines (Basel). 2022 Nov 21;10(11):1976. doi:10.3390/vaccines10111976. PMID: 36423072; PMCID: PMC9692920.
Patel C, Brotherton JM, Pillsbury A, et al. The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent? Euro Surveill. 2018 Oct;23(41):1700737. doi:10.2807/1560-7917.ES.2018.23.41.1700737. PMID: 30326995; PMCID: PMC6194907.
Ward K, Quinn H, Bachelor M, et al. Adolescent school-based vaccination in Australia. Commun Dis Intell Q Rep. 2013 Jun 30;37(2):E156-67. PMID: 24168090.
Smith MA, Winch K, Canfell K, Brotherton JM. Effective HPV vaccination coverage in Australia by number of doses and two-dose spacing: what if one or two doses are sufficient? Tumour Virus Res. 2021 Jun;11:200216. doi:10.1016/j.tvr.2021.200216. PMID: 33864965; PMCID: PMC8190554.
Yuill S, Egger S, Smith M, et al. Has human papillomavirus (HPV) vaccination prevented adverse pregnancy outcomes? Population-level analysis after 8 years of a national HPV vaccination program in Australia. J Infect Dis. 2020 Jul 6;222(3):499-508. doi:10.1093/infdis/jiaa106. PMID: 32386228.
Skinner SR, Davies C, Cooper S, et al. HPV.edu study protocol: a cluster randomised controlled evaluation of education, decisional support and logistical strategies in school-based human papillomavirus (HPV) vaccination of adolescents. University of Wollongong; 2015.
Brotherton J, Hendry A, Dey A, et al. HPV vaccination coverage: slightly improved two-dose schedule completion estimates and historical estimates lower on AIR than HPV Register. Aust N Z J Public Health. 2022 Jun;46(3):394-400. doi:10.1111/1753-6405.13233. PMID: 35357729.
Garland SM, Cornall AM, Brotherton JML, et al. Final analysis of a study assessing genital human papillomavirus genoprevalence in young Australian women, following eight years of a national vaccination program. Vaccine. 2018 May 31;36(23):3221-3230. doi:10.1016/j.vaccine.2018.04.080. PMID: 29724506.
Black E, Richmond R. Prevention of cervical cancer in Sub-Saharan Africa: the advantages and challenges of HPV vaccination. Vaccines (Basel). 2021 Apr 28;9(5):386. doi:10.3390/vaccines9050386. PMID: 33923327; PMCID: PMC8102703.
Maseko FC, Chirwa GC, Muula AS. Lessons learnt during the national introduction of human papillomavirus (HPV) vaccination programmes in 6 African countries: stakeholders' perspectives. S Afr Med J. 2020 Jun 1;110(6):512-518. doi:10.7196/SAMJ.2020.v110i6.14604. PMID: 32880566.
Nnaji CA, Aguolu OG, Onyeaka HK, et al. HPV vaccination in Africa in the COVID-19 era: a cross-sectional survey of healthcare providers’ knowledge, training, and recommendation practices. Front Public Health. 2024 Jan 17;12:1343064. doi:10.3389/fpubh.2024.1343064. PMID: 36926452; PMCID: PMC9846667.
zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer. 2002;2(5):342-350. doi:10.1038/nrc798. PMID: 12044010.
Poljak M, Seme K, Maver PJ, et al. Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Central and Eastern Europe. Vaccine. 2013;31 Suppl 7:H59-70. doi:10.1016/j.vaccine.2013.03.029.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Aleksandra Kujawa, Paulina Krzeszowska , Adrianna Zajączkowska, Jakub Zajączkowski, Kacper Stępniak, Karolina Krochmal, Wojciech Pisarek, Radosław Kuźma, Karolina Marrodán-Wojtczak
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 32
Number of citations: 0
